Relationship between plasma soluble thrombomodulin levels and insulin resistance syndrome in type 2 diabetes: a comparison with von Willebrand factor

Summary:

Endothelial dysfunction plays a pivotal role in the initial stage of atherosclerosis. Insulin resistance is associated with accelerated atherosclerosis, especially coronary heart disease. To elucidate the relationship between endothelial dysfunction and insulin resistance or insulin resistance syndrome in patients with type 2 diabetes, we investigated the correlation between plasma soluble thrombomodulin (TM) and von Willebrand factor (vWF), measures of endothelial dysfunction, and the degree of insulin resistance evaluated by homeostasis assessment models of insulin resistance (HOMA-IR), or variables of insulin resistance syndrome. We studied 53 patients with type 2 diabetes, 23 treated with diet alone and 30 treated with sulfonylureas, who had normal renal function. The plasma soluble TM concentrations were highly correlated with HOMA-IR (r = 0.64, p < 0.0001), the plasma insulin (r = 0.72, p < 0.0001), the systolic blood pressure (r = 0.45, p = 0.0005), and the plasma fibrinogen (r = 0.43, p = 0.0018), while they were inversely correlated with the serum HDL cholesterol concentrations (r = - 0.27, p = 0.0344). The plasma vWF concentrations were positively correlated with HOMA-IR (r = 0.35, p = 0.0151) and the plasma fibrinogen (r = 0.32, p = 0.0203), but not with the plasma insulin, the systolic blood pressure or the HDL cholesterol concentrations. Furthermore, plasma TM, but not vWF, was positively correlated with total number of variables of insulin resistance syndrome (r = 0.45, p = 0.0005). These results indicate that endothelial dysfunction may be associated with the pathogenesis of insulin resistance syndrome as well as insulin resistance, and that the plasma TM might reflect endothelial damage better than the plasma vWF in the state of insulin resistance in patients with type 2 diabetes.

Key words:

Insulin resistance - HOMA-IR - endothelial dysfunction - thrombomodulin - von Willebrand factor

References

• 1 Aso Y, Inukai T, Takemura Y. Mechanism of elevation of serum and urinary thrombomodulin in diabetic patients: possible application as a marker for vascular endothelial injury.  Metabolism. 47 362-365 1998; 
• 2 Aso Y, Fujiwara Y, Takebayashi K, Tayama K, Inukai T, Takemura Y. Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes.  Clin Chim Acta. 301 135-145 2000; 
• 3 Aso Y, Sato A, Tanaka K, Fujiwara Y, Satoh H, Narimatsu M, Naito T, Inukai T, Takemura Y. Thrombomodulin and thrombin-antithrombin-III complex: tool for possible markers of disease activity in microscopic polyarteritis and polyarteritis nodosa.  Dokkyo J Med Sci. 23 201-206 1996; 
• 4 Brunzell J D, Hokanson J E. Dyslipidemia of central obesity and insulin resistance.  Diabetes Care. 22 C10-C13 1999; 
• 5 Castillo C, Bogardus C, Bergman R, Thuillez P, Lillioja S. Interstitial insulin concentrations determine glucose uptake rates but not insulin resistance in lean and obese men.  J Clin Invest. 93 10-16 1994; 
• 6 DeFronzo R A. Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview.  Diabetologia. 35 389-397 1992; 
• 7 Dittman W A, Majerus P W. Structure and function of thromobomodulin: a natural anticoagulant.  Blood. 75 329-336 1990; 
• 8 Emoto M, Kawagishi T, Nishizawa Y, Shoji T, Kaekawa K, Okuno Y, Hiura Y, Morii H, Kanda H. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas.  Diabetes Care. 22 818-822 1999; 
• 9 Esmon C T. The roles of protein C and thrombomodulin in the regulation of blood coagulation.  J Biol Chem. 264 4743-4746 1989; 
• 10 Esmon C T, Owen W G. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.  Proc Natl Acad Sci USA. 78 2249-2252 1981; 
• 11 Haffner S M. The insulin resistance syndrome revisited.  Diabetes Care. 19 275-277 1996; 
• 12 Hosaka Y, Takahashi Y, Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B.  Thromb Haemost. 79 371-377 1998; 
• 13 Imperatore G, Riccardia G, Iovine C, Rivellese A A, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study.  Diabetes Care. 21 649-665 1998; 
• 14 Inukai T, Fujiwara Y, Tayama K, Aso Y, Takemura Y. Clinical significance of measurements of urinary and serum thrombomodulin in patients with non-insulin-dependent diabetes mellitus.  Diabetes Res Clin Prac. 33 99-104 1996; 
• 15 Ishii H, Nakano M, Tsubouchi J, Ishikawa T, Uchiyama H, Hiraishi S, Tahara C, Miyajima Y, Kazama M. Establishment of enzyme immunoassay of human thrombomodulin in plasma and urine using monoclonal antibodies.  Thromb Haemost. 63 157-162 1990; 
• 16 Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells.  Thromb Haemost. 65 618-623 1991; 
• 17 Ishii H, Majerus P W. Thrombomodulin is present on human plasma and urine.  J Clin Invest. 76 2178-2181 1985; 
• 18 Iwashima Y, Sato T, Watanabe K, Ooshima E, Hiraishi S, Ishii H, Kazama M, Makino I. Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy.  Diabetes. 39 983-988 1990; 
• 19 Juhan-Vague I, Thompson S G, Jespersen J. Involvement of the haemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris.  Arterioscler Thromb. 13 1865-1873 1993; 
• 20 Laight D W, Carrier M J, Anggard E E. Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy.  Diabetes Metab Res Rev. 15 274-282 1999; 
• 21 Mannucci P M. Platelet von Willebrand factor in inherited and acquired bleeding disorders.  Proc Natl Acad Sci USA. 92 2428-2432 1995; 
• 22 Mannucci P M. von Willebrand factor: a marker of endothelial damage?.  Arteriorscler Thromb Vasc Biol. 18 1359-1362 1998; 
• 23 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 28 412-419 1985; 
• 24 Pinkney J H, Stehouwer C DA, Coppack S W, Yudkin J S. Endothelial dysfunction: cause of the insulin resistance syndrome.  Diabetes. 46 S9-S13 1997; 
• 25 Reaven G M. Role of insulin resistance in human disease.  Diabetes. 37 1595-1607 1988; 
• 26 Ross R. The pathogenesis of atherosclerosis: a perspective for 1990s.  Nature. 362 801-809 1993; 
• 27 Steinberg H O, Chaker H, Leaming R, Johnson A, Brechtel G, Baron A D. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance.  J Clin Invest. 97 2601-2610 1996; 
• 28 Suzuki K, Nishioka J, Hayashi T, Kosaka Y. Functionally active thrombomodulin is present in human platelets.  J Biochem. 104 628-632 1988; 
• 29 Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases.  Blood. 76 2024-2029 1990; 
• 30 Takaya M, Ichikawa Y, Kobayashi N, Kawada T, Shimizu H, Uchiyama M, Moriuchi J, Watanabe K, Arimori S. Serum thrombomodulin and anticardiolipin antibodies in patients with systemic lupus erythematosus.  Clin Exp Rheumatol. 9 495-499 1991; 
• 31 Tanaka A, Ishii H, Hiraishi S, Kazama M, Maezawa H. Increased thrombomodulin values in plasma of diabetic men with microangiopathy.  Clin Chem. 37 269-272 1991; 
• 32 Taniguchi A, Fukushima M, Sakai M, Kataoka K, Nagata I, Doi K, Arakawa H, Nagasaka S, Tokuyama K, Nakai Y. The role of the body mass index and triglyceride levels in identifying insulin-sensitive and insulin-resistant variants in Japanese non-insulin-dependent diabetic patients.  Metabolism. 49 1001-1005 2000; 
• 33 Thomas K B, Sutor A H, Zieger B, Jessat U, Grohmann A, Wendisch J, Budde U, von Kries R, Hasler K, Tune E P, Choong S C. Ein einfacher Test fur die Bestimmung der Funktion des Von-Willebrand Faktors: die Kollagenbindungsaktivitat.  Hämostaseologie. 14 133-139 1994; 
• 34 Valek J, Valkova L, Vlasakova Z, Topinka V. Increased fibrinogen levels in the offspring of hypertensive men. Relation with hyperinsulinemia and the metabolic syndrome.  Arterioscler Thromb Vasc Biol. 15 2229-2233 995; 
• 35 Yudkin J S. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent?.  Diabetes Care. 22 C25-C30 1999; 
• 36 Yudkin J S. Lipids, thrombosis and cardiovascular disease in diabetes.  Proc Nutr Soc. 56 273-280 1997;